Cardiovascular Risk Management
Research activity centers on lipid-lowering therapy and cardiovascular prevention, with attention to treatment combinations used in managing elevated cholesterol and broader atherosclerotic risk.
- Statin-based therapy
- Cholesterol absorption inhibition
- Combined lipid-modifying regimens
The sponsor’s clinical research includes fixed-dose combinations involving bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin, reflecting a focus on therapies used in hyperlipidaemia management.
Fixed-Dose Combination Medicines
Clinical interest extends to combination formulations designed to simplify treatment with multiple cardiometabolic agents in a single tablet.
- Bempedoic acid and ezetimibe combinations
- Single-tablet co-formulations
- Tablet-to-tablet bioequivalence
These studies examine how fixed-dose products compare with separately administered tablets, supporting development in oral combination therapy for lipid control.
Pharmacokinetic Equivalence Assessment
The sponsor’s portfolio includes work in bioequivalence and comparative exposure assessment for oral small-molecule medicines.
- Relative bioavailability
- Oral formulation comparison
- Therapeutic interchangeability
This area supports evaluation of whether fixed-dose combinations deliver comparable systemic exposure to individual components, a key issue in regulatory development for cardiovascular medicines.
Oral Lipid-Lowering Treatment Development
Research is directed toward oral therapies intended for long-term use in patients requiring LDL-cholesterol reduction and related metabolic management.
- HMG-CoA reductase inhibition
- Cholesterol synthesis modulation
- Adjunctive lipid therapy
The funded studies align with development of cardiovascular medicines that combine established and newer lipid-modifying mechanisms in a single treatment option.
